Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Ephedrine Sulfate Injection USP, 50 mg/mL single-dose vials, the company announced through an exchange filing.
Ephedrine Sulfate Injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara (India).
Ephedrine Sulfate Injection USP, 50 mg/mL had annual sales of USD 52 mn in the United States.
The group now has 368 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.
'If Someone Like You...': Salman Khan's Sister Arpita Khan Sharma REACTS To Nadim Nadz & Mahhi Vij Dating Rumours
Using Other Bank ATMs Gets Costlier For SBI Customers, Here's Who Will Pay More & Who Is Still Safe?
Dog Thrown From Car Windshield Lands On Feet During High-Speed Police Chase - Viral Video
'PSLV-C62 Mission Witnesses Disturbance At PS3 Stage, Deviation In Vehicle's Flight Path': ISRO
